pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in

Novartis, Merck, GlaxoSmithKline (GSK), Gilead, Bayer, AstraZeneca, AbbVie and Takeda offered their opinions on recent FDA draft guidance on potential drug-drug interactions (DDIs) with pH modulating agents such as proton-pump inhibitors (PPI) or acid reducing agents (ARA).